Lyndsey Linke

Company: SiVEC Biotechnologies

Job title: CEO

Seminars:

Advancing PAN-RAS Inhibitors: Tackling Mutational Heterogeneity in Diverse Cancers Using Cutting-Edge Modalities 9:45 am

Alternatives to small-molecule drugs for mutant KRAS targeting Rationale for bacteria-mediated intracellular delivery of single-domain antibodies (VHH) as a next-generation therapy Introducing SVC-KRAb: a first-in-class pan-KRAS-targeting therapeuticRead more

day: Day One